Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By

UsernamePublicRestriction
UsernamePublicRestriction

FDA advisory committee cuts

This article was originally published in The Tan Sheet

Executive Summary

Responding to a Feb. 10 order by President Clinton that each department and agency terminate not less than one-third of advisory committees subject to FACA and not required by statute, each FDA center and office is in the process of drawing up a list of options on where cuts might be made and the pros and cons of each option. The options range from cutting some or all of the committees, combining committees, reducing the number of members, decreasing the frequency of meetings, and using government facilities only for committee meetings. Ann Witt, special assistant to FDA Deputy Commissioner for Operations Jane Henney, is coordinating the review. HHS Secretary Shalala and FDA Commissioner Kessler must submit the recommendations to OMB by May 10.
Advertisement

Topics

Advertisement
UsernamePublicRestriction

Register

PS081293

Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts

Cancel